AI Insight
An investigational inhaled drug called mosliciguat, which activates soluble guanylate cyclase (sGC), has shown marked and consistent positive effects in a phase 2 clinical trial for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This condition represents one of the most difficult forms of pulmonary vascular disease to treat. The drug builds on decades of research into pulmonary vascular mechanisms and is now advancing to further stages of clinical development.
Why it matters
PH-ILD is a serious and challenging medical condition with limited treatment options, affecting patients who have both lung scarring and elevated blood pressure in the lungs. This inhaled therapeutic approach could potentially offer a new treatment avenue for patients suffering from this rare and difficult-to-manage disease combination.
Understand the Science
A therapeutic principle rooted in decades of pulmonary vascular research is entering a new stage of clinical development. The investigational inhaled drug mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced marked and consistent effects in a randomized phase 2 study involving patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), one of the most challenging forms of pulmonary vascular disease.
Source: Inhaled drug shows promise for rare lung disease combination